このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Cardiovascular and Bone Mineral Markers in Dialysis Patients and Healthy Controls

2026年9月9日 更新者:Veysel Baran TOMAR、Gazi University

Prospective Comparative Evaluation of the Biochemical and Clinical Effects of Different Dialysis Modalities on Cardiovascular Status and Bone Mineral Metabolism

This observational study will compare cardiovascular status, bone mineral metabolism, systemic inflammation, body composition, functional status, quality of life, pruritus, and pain among patients receiving different renal replacement therapy modalities and healthy controls.

Adult participants will be included in four groups: maintenance hemodialysis, continuous ambulatory peritoneal dialysis, automated peritoneal dialysis, and healthy controls. No new treatment, drug, dialysis modality, or experimental device will be assigned as part of the study. Participants will continue their routine clinical care.

Serum interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), fibroblast growth factor-23 (FGF-23), and sclerostin levels will be measured. Arterial stiffness will be assessed using pulse wave velocity (PWV), and body composition will be assessed using the Body Composition Monitor (BCM). Handgrip strength, quality of life, pruritus, and pain scores will also be evaluated.

The study will also explore correlations between biochemical biomarkers, arterial stiffness, body composition, and patient-reported outcomes. In the automated peritoneal dialysis group, objective treatment adherence will additionally be assessed using the Sharesource (Baxter/Vantive) cloud-based remote patient monitoring platform.

調査の概要

状態

積極的、募集していない

条件

詳細な説明

Patients with end-stage kidney disease receiving renal replacement therapy have a high burden of cardiovascular disease, chronic inflammation, mineral and bone metabolism abnormalities, altered body composition, impaired quality of life, pruritus, and pain. Hemodialysis and peritoneal dialysis differ in clearance patterns, fluid management, and treatment delivery, which may influence biochemical, vascular, nutritional, and patient-reported outcomes.

This is a single-center observational clinical study including adult patients receiving routine renal replacement therapy and healthy controls. Participants will not be assigned to any intervention by the study protocol. Hemodialysis, continuous ambulatory peritoneal dialysis (CAPD), and automated peritoneal dialysis (APD) treatments will continue according to routine clinical practice and the decisions of the treating physicians.

The study will include 100 participants in four groups: 40 patients receiving maintenance hemodialysis, 20 patients receiving CAPD, 20 patients receiving APD, and 20 healthy controls. Dialysis patients will be evaluated at baseline, Month 3, Month 6, and Month 12. Healthy controls will be evaluated at baseline only.

The main objective is to compare patients receiving different dialysis modalities and healthy controls in terms of bone mineral metabolism, systemic inflammation, endothelial dysfunction, arterial stiffness, body composition, functional status, quality of life, pruritus, and pain. Serum sclerostin and fibroblast growth factor-23 (FGF-23) will be evaluated as bone mineral metabolism biomarkers. Serum interleukin-6 (IL-6) and vascular cell adhesion molecule-1 (VCAM-1) will be evaluated as inflammatory and endothelial dysfunction-related biomarkers. These biomarkers will be measured using enzyme-linked immunosorbent assay (ELISA).

For hemodialysis patients, blood samples will be obtained immediately before a mid-week dialysis session through the existing vascular access. For CAPD patients, APD patients, and healthy controls, fasting venous blood samples will be obtained in the morning. Serum samples will be processed and stored according to laboratory procedures until batch analysis.

Arterial stiffness will be assessed using pulse wave velocity (PWV). Body composition and fluid status will be assessed by bioimpedance analysis using the Fresenius Body Composition Monitor (BCM). Body composition parameters will include overhydration, extracellular water to total body water ratio, intracellular water, lean tissue index, body cell mass. Handgrip strength will be measured as a functional parameter.

Patient-reported outcomes will be assessed using the Kidney Disease Quality of Life-36 (KDQOL-36), the Uremic Pruritus in Dialysis Patients (UP-Dial) questionnaire, and the Short-Form McGill Pain Questionnaire (SF-MPQ), as applicable. In healthy controls, kidney disease-specific questionnaire components will not be applied; instead, the 12-Item Short Form Health Survey (SF-12) will be used to assess general health-related quality of life.

The study will also evaluate correlations between molecular biomarkers, instrumental measurements, and clinical scores. Specifically, the relationships between elevated biomarker levels, increased arterial stiffness, altered body composition, lower quality of life, pruritus, and pain burden will be explored.

As an additional objective, objective treatment adherence will be assessed in the APD group using data transferred from home cycler devices to the Sharesource (Baxter/Vantive) cloud-based remote patient monitoring platform. Adherence-related variables will include the percentage of completed sessions, lost dwell time, differences between prescribed and delivered ultrafiltration, and device bypass or manual intervention alarms. Full treatment adherence will be defined as completion of at least 90% of the prescribed dialysis session number and total prescribed dialysis duration.

No additional invasive procedure will be performed other than standard blood sampling for biomarker measurements. Pulse wave velocity and body composition measurements are non-invasive and will be performed using devices used in routine clinical practice.

研究の種類

観察的

入学 (推定)

100

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Ankara
      • Ankara、Ankara、トルコ(Türkiye)、06500
        • Gazi University Faculty of Medicine, Department of Nephrology

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

Adult participants will be recruited from the Gazi University Faculty of Medicine nephrology outpatient clinic and dialysis units. The study population will include four cohorts: patients receiving maintenance hemodialysis, patients receiving continuous ambulatory peritoneal dialysis, patients receiving automated peritoneal dialysis, and healthy controls without known kidney disease. Dialysis patients must have been receiving regular dialysis treatment for at least 6 months. Healthy controls will have no known kidney disease, systemic inflammatory disease, or active malignancy.

説明

Inclusion Criteria:

  • Age 18 to 80 years.
  • For dialysis cohorts: diagnosis of end-stage kidney disease and receiving maintenance hemodialysis or peritoneal dialysis.
  • For dialysis cohorts: receiving regular hemodialysis, continuous ambulatory peritoneal dialysis, or automated peritoneal dialysis for at least 6 months.
  • For healthy controls: no known kidney disease, with estimated glomerular filtration rate greater than 90 mL/min/1.73 m².
  • For healthy controls: no known systemic inflammatory disease or active malignancy.
  • Able to comply with planned study procedures, including pulse wave velocity measurement, Body Composition Monitor assessment, questionnaires, and biomarker measurements.
  • Able and willing to provide written informed consent.

Exclusion Criteria:

  • Inability to comply with study measurements or questionnaire assessments.
  • Refusal or inability to provide written informed consent.
  • Age younger than 18 years or older than 80 years.
  • Acute infection.
  • Recent major surgical intervention.
  • Active malignancy.
  • Terminal illness with limited life expectancy.
  • Mental, cognitive, physical, or clinical condition preventing participation in study procedures.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Maintenance Hemodialysis
Adult patients with end-stage kidney disease who have been receiving maintenance hemodialysis for at least 6 months. Participants in this cohort will continue their routine hemodialysis treatment three times weekly according to standard clinical practice. No intervention will be assigned by the study protocol. Blood samples, pulse wave velocity, body composition measurements, handgrip strength, and patient-reported outcome assessments will be performed at baseline, Month 3, Month 6, and Month 12.
Continuous Ambulatory Peritoneal Dialysis
Adult patients with end-stage kidney disease who have been receiving continuous ambulatory peritoneal dialysis (CAPD) for at least 6 months. Participants in this cohort will continue their routine CAPD treatment according to standard clinical practice. No intervention will be assigned by the study protocol. Blood samples, pulse wave velocity, body composition measurements, handgrip strength, and patient-reported outcome assessments will be performed at baseline, Month 3, Month 6, and Month 12.
Automated Peritoneal Dialysis
Adult patients with end-stage kidney disease who have been receiving automated peritoneal dialysis (APD) for at least 6 months. Participants in this cohort will continue their routine APD treatment according to standard clinical practice. No intervention will be assigned by the study protocol. Blood samples, pulse wave velocity, body composition measurements, handgrip strength, and patient-reported outcome assessments will be performed at baseline, Month 3, Month 6, and Month 12. Objective treatment adherence will also be assessed using data transferred from home cycler devices to the Sharesource cloud-based remote patient monitoring platform.
Healthy Controls
Adult healthy controls without known kidney disease, systemic inflammatory disease, or active malignancy. Healthy controls will not receive any intervention assigned by the study protocol. Baseline blood samples, pulse wave velocity, body composition measurements, handgrip strength, pain assessment, and general health-related quality of life assessment using the 12-Item Short Form Health Survey (SF-12) will be performed. Healthy controls will be evaluated at baseline only and will not undergo longitudinal follow-up.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Serum Interleukin-6 (IL-6) Concentration
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum interleukin-6 (IL-6) concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum IL-6 concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline IL-6 concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Concentration
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum vascular cell adhesion molecule-1 (VCAM-1) concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum VCAM-1 concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline VCAM-1 concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Serum Sclerostin Concentration
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum sclerostin concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum sclerostin concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline sclerostin concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Serum Fibroblast Growth Factor-23 (FGF-23) Concentration
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Serum fibroblast growth factor-23 (FGF-23) concentration will be measured using enzyme-linked immunosorbent assay (ELISA). Change in serum FGF-23 concentration from baseline to Month 12 will be evaluated in dialysis cohorts, and baseline FGF-23 concentrations will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Pulse Wave Velocity (PWV) Measured in m/s
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Pulse wave velocity (PWV) will be measured in meters per second (m/s) as a single parameter of arterial stiffness. Changes in PWV over time will be evaluated in dialysis cohorts, and baseline PWV values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Handgrip Strength Measured by Hand Dynamometer
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Handgrip strength will be measured in kilograms (kg) using a hand dynamometer as a functional parameter. Changes in handgrip strength over time will be evaluated in dialysis cohorts, and baseline handgrip strength values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Kidney Disease Quality of Life-36 (KDQOL-36) Score
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Health-related quality of life will be evaluated using the Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire in dialysis cohorts. Changes in KDQOL-36 scores over time will be evaluated in hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis cohorts. Higher scores indicate better health-related quality of life and a better outcome.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Uraemic Pruritus in Dialysis Patients (UP-Dial) Score
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Pruritus severity will be evaluated using the Uraemic Pruritus in Dialysis Patients (UP-Dial) scale in dialysis cohorts. The UP-Dial total score ranges from 0 to 56, with higher scores indicating more severe pruritus and a worse outcome.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Short-Form McGill Pain Questionnaire (SF-MPQ) Total Pain Rating Index Score
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Pain will be evaluated using the Short-Form McGill Pain Questionnaire (SF-MPQ) total Pain Rating Index score. The SF-MPQ total Pain Rating Index score is calculated from 15 pain descriptors, each scored from 0 to 3, resulting in a total score range of 0 to 45. Higher scores indicate greater pain severity and a worse outcome. Changes over time will be evaluated in dialysis cohorts, and baseline values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Overhydration (OH) Measured by Body Composition Monitor
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Overhydration (OH) will be measured in liters (L) using the Body Composition Monitor (BCM). Changes in OH over time will be evaluated in dialysis cohorts, and baseline OH values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Extracellular Water to Total Body Water Ratio (ECW/TBW)
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
The extracellular water to total body water ratio (ECW/TBW) will be assessed using the Body Composition Monitor (BCM). Changes in ECW/TBW over time will be evaluated in dialysis cohorts, and baseline ECW/TBW values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Intracellular Water (ICW) Measured by Body Composition Monitor
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Intracellular water (ICW) will be measured in liters (L) using the Body Composition Monitor (BCM). Changes in ICW over time will be evaluated in dialysis cohorts, and baseline ICW values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Lean Tissue Index (LTI) Measured by Body Composition Monitor
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Lean tissue index (LTI) will be measured in kg/m² using the Body Composition Monitor (BCM). Changes in LTI over time will be evaluated in dialysis cohorts, and baseline LTI values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Change in Body Cell Mass Measured by Body Composition Monitor
時間枠:Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.
Body cell mass will be measured in kilograms (kg) using the Body Composition Monitor (BCM). Changes in body cell mass over time will be evaluated in dialysis cohorts, and baseline body cell mass values will be compared between dialysis modality groups and healthy controls.
Baseline (July 2026), Month 3 (October 2026), Month 6 (January 2027), and Month 12 (July 2027) for dialysis cohorts; baseline only (July 2026) for healthy controls.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月1日

一次修了 (推定)

2027年7月1日

研究の完了 (推定)

2027年7月1日

試験登録日

最初に提出

2026年6月30日

QC基準を満たした最初の提出物

2026年6月30日

最初の投稿 (実際)

2026年7月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月14日

QC基準を満たした最後の更新が送信されました

2026年9月9日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • GAZI-HD-PD-2026

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) are not planned to be shared publicly. The study is a single-center observational study with a limited number of participants, and the dataset may include sensitive clinical, laboratory, questionnaire, and treatment adherence data. All data will be stored in coded form and managed in accordance with institutional policies, ethical requirements, and applicable data protection regulations. De-identified aggregate results may be reported in scientific publications.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。